Calithera Biosciences Reports Third Quarter 2015 Financial Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Calithera Biosciences (CALA) Reports Q3 Loss of $0.49/Share
November 10, 2015 9:43 AM ESTCalithera Biosciences (NASDAQ: CALA) reported Q3 EPS of ($0.49), versus ($16.85) reported last year.
Anticipated Upcoming Milestones
Hematologic Phase 1 clinical trial data by year end 2015Initiation of six CB-839 combination expansion cohorts by year end 2015CB-839 combination therapy data in... MoreCalithera Biosciences (CALA) Files $150M Common Stock Shelf
November 10, 2015 9:41 AM ESTCalithera Biosciences (NASDAQ: CALA) filed a registration with the U.S. SEC to sell up to $150 million worth of common stock.
... MoreLeerink Partners Reiterates Outperform on Calithera Biosciences (CALA) Following 3Q
November 10, 2015 7:00 AM ESTLeerink Partners reiterated an Outperform rating and $13.00 price target on Calithera Biosciences (NASDAQ: CALA) following the company's 3Q earnings report. CALA reported 3Q15 EPS of ($0.49), slightly better than consensus estimates of ($0.54).
Analyst Paul Matteis commented, "After the close, CALA reported 3Q15 EPS of ($0.49), in-line with... More
